CY1121298T1 - Μεθοδοι θεραπειας διαμεσολαβουμενης απο αντισωμα απορριψης σε ασθενεις με μεταμοσχευση οργανου με παρεμποδιστη c1-εστερασης - Google Patents

Μεθοδοι θεραπειας διαμεσολαβουμενης απο αντισωμα απορριψης σε ασθενεις με μεταμοσχευση οργανου με παρεμποδιστη c1-εστερασης

Info

Publication number
CY1121298T1
CY1121298T1 CY20191100119T CY191100119T CY1121298T1 CY 1121298 T1 CY1121298 T1 CY 1121298T1 CY 20191100119 T CY20191100119 T CY 20191100119T CY 191100119 T CY191100119 T CY 191100119T CY 1121298 T1 CY1121298 T1 CY 1121298T1
Authority
CY
Cyprus
Prior art keywords
antibody
transplantation
patients
methods
instruction instrument
Prior art date
Application number
CY20191100119T
Other languages
Greek (el)
English (en)
Inventor
Colin Broom
Marc E. UKNIS
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121298(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of CY1121298T1 publication Critical patent/CY1121298T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20191100119T 2013-11-22 2019-01-29 Μεθοδοι θεραπειας διαμεσολαβουμενης απο αντισωμα απορριψης σε ασθενεις με μεταμοσχευση οργανου με παρεμποδιστη c1-εστερασης CY1121298T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907550P 2013-11-22 2013-11-22
US201462029086P 2014-07-25 2014-07-25
PCT/US2014/066784 WO2015077543A1 (en) 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Publications (1)

Publication Number Publication Date
CY1121298T1 true CY1121298T1 (el) 2020-05-29

Family

ID=52016153

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100119T CY1121298T1 (el) 2013-11-22 2019-01-29 Μεθοδοι θεραπειας διαμεσολαβουμενης απο αντισωμα απορριψης σε ασθενεις με μεταμοσχευση οργανου με παρεμποδιστη c1-εστερασης

Country Status (24)

Country Link
US (3) US9895428B2 (https=)
EP (3) EP4162947A1 (https=)
JP (5) JP6431912B2 (https=)
KR (2) KR102312817B1 (https=)
CN (2) CN111388655A (https=)
AU (2) AU2014352846B2 (https=)
BR (1) BR112016011499A2 (https=)
CA (1) CA2930964A1 (https=)
CY (1) CY1121298T1 (https=)
DK (1) DK3071219T3 (https=)
ES (1) ES2708655T3 (https=)
HR (1) HRP20190184T1 (https=)
HU (1) HUE041809T2 (https=)
LT (1) LT3071219T (https=)
ME (1) ME03318B (https=)
MX (2) MX378834B (https=)
NZ (2) NZ719724A (https=)
PL (1) PL3071219T3 (https=)
PT (1) PT3071219T (https=)
RS (1) RS58343B1 (https=)
SG (1) SG10201804326SA (https=)
SI (1) SI3071219T1 (https=)
SM (1) SMT201900042T1 (https=)
WO (1) WO2015077543A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor
CA3075686A1 (en) * 2017-09-15 2019-03-21 Cedars-Sinai Medical Center Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) * 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
US20220073605A1 (en) * 2018-12-20 2022-03-10 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
AU2020327043A1 (en) * 2019-08-08 2022-02-24 Cedars-Sinai Medical Center Methods of improving organ function
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
AU2021381360A1 (en) * 2020-11-20 2023-06-22 Csl Behring Gmbh Method for treating antibody-mediated rejection
CN113035369B (zh) * 2021-03-10 2021-12-03 浙江大学 一种肾移植抗感染药物剂量预测模型的构建方法
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
WO2024152030A1 (en) * 2023-01-13 2024-07-18 The Uab Research Foundation Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4212278B2 (ja) * 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
US20090118162A1 (en) 2005-06-07 2009-05-07 Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
RS53864B1 (sr) * 2006-03-02 2015-08-31 Alexion Pharmaceuticals, Inc. Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa
DK2758076T3 (en) * 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
CA2901225C (en) * 2013-03-08 2023-09-19 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
BR112015023207A8 (pt) * 2013-03-15 2018-01-23 Shire Viropharma Inc composições de ci-inh e métodos para prevenção e tratamento de desordens associadas à deficiência de inibidor de c1 esterase.
NZ719724A (en) * 2013-11-22 2022-08-26 Takeda Pharmaceuticals Co Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Also Published As

Publication number Publication date
EP3071219B1 (en) 2018-11-14
CA2930964A1 (en) 2015-05-28
JP6620206B2 (ja) 2019-12-11
BR112016011499A2 (pt) 2020-10-27
AU2014352846A1 (en) 2016-06-02
SI3071219T1 (sl) 2019-03-29
JP2022179637A (ja) 2022-12-02
RS58343B1 (sr) 2019-03-29
MX2016006656A (es) 2016-09-06
JP2016537380A (ja) 2016-12-01
HUE041809T2 (hu) 2019-05-28
KR20160079821A (ko) 2016-07-06
JP2019023233A (ja) 2019-02-14
KR102312817B1 (ko) 2021-10-13
CN105744949A (zh) 2016-07-06
US20150147319A1 (en) 2015-05-28
JP2021063141A (ja) 2021-04-22
ME03318B (me) 2019-10-20
KR20210125118A (ko) 2021-10-15
CN111388655A (zh) 2020-07-10
MX378834B (es) 2025-03-11
PT3071219T (pt) 2019-02-06
HRP20190184T1 (hr) 2019-03-22
KR102384814B1 (ko) 2022-04-08
MX2021000332A (es) 2021-04-13
EP4162947A1 (en) 2023-04-12
AU2014352846B2 (en) 2019-10-03
LT3071219T (lt) 2019-01-10
WO2015077543A1 (en) 2015-05-28
JP2019001831A (ja) 2019-01-10
SG10201804326SA (en) 2018-06-28
NZ719724A (en) 2022-08-26
US20180104319A1 (en) 2018-04-19
DK3071219T3 (en) 2019-02-25
EP3494988A1 (en) 2019-06-12
ES2708655T3 (es) 2019-04-10
JP6431912B2 (ja) 2018-11-28
EP3494988B1 (en) 2022-08-03
NZ759187A (en) 2022-08-26
PL3071219T3 (pl) 2019-04-30
US20200360495A1 (en) 2020-11-19
AU2020200015B2 (en) 2022-03-10
AU2020200015A1 (en) 2020-01-30
SMT201900042T1 (it) 2019-02-28
EP3071219A1 (en) 2016-09-28
US9895428B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
CY1121298T1 (el) Μεθοδοι θεραπειας διαμεσολαβουμενης απο αντισωμα απορριψης σε ασθενεις με μεταμοσχευση οργανου με παρεμποδιστη c1-εστερασης
ECSP20069404A (es) Piridazinonas como inhibidoras de parp7
CY1125058T1 (el) Δοσολογικο σχημα βαλβεναζινης για την αντιμετωπιση των κινητικων διαταραχων υπερκινητικοτητας
IL270982A (en) Articles of manufacture and methods for treatment using adoptive cell therapy
CY1125028T1 (el) Χρηση οξυγονωμενης θειικης χοληστερολης (ocs) για την αντιμετωπιση οξειας ηπατικης ανεπαρκειας
MX2018006745A (es) Metodos de tratamiento de neoplasias malignas.
IL291183A (en) Tools and methods for vaginal access
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
EP3551100A4 (en) MEDICAL DEVICES FOR TREATING HARD TISSUES AND RELATED PROCESSES
MX2016007312A (es) Moleculas de union al antigeno, cuya actividad de union al antigeno varia de acuerdo con la concentracion de los compuestos y bibliotecas de dichas moleculas.
CY1122185T1 (el) Ιατρικη χρηση ενωσεων αρτεμισινινης και αγωνιστων γεφυρινης
EP3666888A4 (en) T-CELL ACTIVATION METHOD FOR CANCER TREATMENT
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EP3585778A4 (en) METHODS OF TREATING PATIENTS WITH HEMATOLOGICAL MALIGNACIES
CY1124191T1 (el) Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις
CY1124759T1 (el) Μεθοδοι για τη θεραπεια της οξειας νεφρικης βλαβης
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
EP3418378C0 (en) NOVEL METHODS FOR PRODUCTION AND USE OF INDUCED NEURAL BORDER STEM CELLS IN HUMANS
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
DK3383446T3 (da) Fremgangsmåde til inaktivering af xenoantigener i biologiske væv
EP3810006A4 (en) OPTICAL NETWORK FOR TISSUE PROCESSING
IL290202A (en) Methods and kits for identifying thrombus origin and optimizing post-ischemic event treatment
IL309934A (en) Anti-cd36 antibodies and their use to treat cancer